SMA Research Platform

Evidence graph for Spinal Muscular Atrophy

Biology-first target discovery
Christian Fischer / Bryzant Labs
14,766Targets
453Trials
84Drugs
7Datasets
6,987Sources
64,683Claims
72,052Evidence
29,649Hypotheses
DRUGapprovedsmall molecule

N-Acetylcysteine

Mechanism

Glutathione precursor / antioxidant

Related claims (9)

TypePredicateConfSource
neuroprotectionN-acetylcysteine (NAC) rescues motor neuron degeneration in SMA long-term cultures.53%26586529
drug efficacyN-acetylcysteine (NAC) ameliorates reduction in mitochondrial membrane potential in SMA spinal motor neurons.53%26586529
drug efficacyN-acetylcysteine (NAC), an antioxidant, prevents apoptosis and motor neuron death in SMN-knockdown models.51%23208423
drug efficacyN-acetylcysteine rescues reduced vitality and altered morphology in SMA cortical neurons (demonstrated in vitro).50%PMID:41402453
neuroprotectionN-acetylcysteine (NAC) rescues motor neuron degeneration in SMA long-term cultures (demonstrated in vitro).50%PMID:26586529
drug efficacyN-acetylcysteine (NAC) ameliorates the reduction in mitochondrial membrane potential in SMA spinal motor neurons (demonstrated in vitro).50%PMID:26586529
drug efficacyN-acetylcysteine (NAC) mitigates impairment in mitochondrial transport and morphology in SMA spinal motor neurons.45%26586529
drug efficacyN-acetylcysteine rescued all the parameters of SMA cortical neurons (demonstrated in vitro)45%41402453
drug efficacyN-acetylcysteine (NAC) mitigates impairment in mitochondrial transport and morphology in SMA spinal motor neurons (demonstrated in vitro).42%PMID:26586529

Off-Target Findings (0)

No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.

Login → Command Center